Our findings, however, do support a previously unappreciated role of this IL-1 isoform in post-MI cardiac remodeling and fibrosis, suggesting that specific IL-1α antagonists could represent a possible therapeutic approach to limit adverse post-MI remodeling. This evidence concerns the gene IL1A and myocardial infarction.